Source:http://linkedlifedata.com/resource/pubmed/id/11001391
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2001-1-3
|
| pubmed:abstractText |
The addition of oxaliplatin (L-OHP) to a 5-fluorouracil (5-FU)/ leucovorin (FA) regimen was retrospectively evaluated in 35 consecutive advanced colorectal cancer patients after progression of disease. L-OHP, 25 mg/m2/day, was infused from 10.00-22.00 with a peak flow at 16.00 while 5-FU, 700 mg/m2/day and FA, 150 mg/m2/day of the I-form or 300 mg/m2/day of the racemic form, from 22.00 to 10.00 with a nocturnal peak at 4.00, for 5 days every 3 weeks in 24 patients and for 4 days every 2 weeks in the other 11. Diarrhea and sensitive neuropathy were the most relevant types of toxicity (17% of patients). An objective response was achieved in 8/35 patients (23%) [95% CL 9-37], stabilization in 15 patients (43%) which included five minor responses, and progression in 12. There was no relevant difference in quality of life assessed with the EORTC QLQ C30+3 questionnaire before and after treatment. Median duration of response and median progression-free survival were 6 months; median overall survival was 11 months. This retrospective study showed that it is possible to reverse resistance to chronomodulated 5-FU by adding chronomodulated L-OHP to the previous regimen; comparison with different schedules of this combination should be performed in order to identify the best tolerated and active regimen as second-line treatment of advanced colorectal cancer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0959-4973
|
| pubmed:author |
pubmed-author:AschelterA MAM,
pubmed-author:Bensmaine,
pubmed-author:Bertheault-CvitkovicFF,
pubmed-author:BrienzaSS,
pubmed-author:CaterinoMM,
pubmed-author:CosimelliMM,
pubmed-author:GarufiCC,
pubmed-author:GiannarelliDD,
pubmed-author:GiuntaSS,
pubmed-author:LéviFF,
pubmed-author:NisticòCC,
pubmed-author:PugliesePP,
pubmed-author:TerzoliEE
|
| pubmed:issnType |
Print
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
495-501
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:11001391-Adult,
pubmed-meshheading:11001391-Aged,
pubmed-meshheading:11001391-Antimetabolites, Antineoplastic,
pubmed-meshheading:11001391-Chronotherapy,
pubmed-meshheading:11001391-Colorectal Neoplasms,
pubmed-meshheading:11001391-Drug Resistance,
pubmed-meshheading:11001391-Drug Resistance, Neoplasm,
pubmed-meshheading:11001391-Female,
pubmed-meshheading:11001391-Fluorouracil,
pubmed-meshheading:11001391-Follow-Up Studies,
pubmed-meshheading:11001391-Humans,
pubmed-meshheading:11001391-Leucovorin,
pubmed-meshheading:11001391-Liver Neoplasms,
pubmed-meshheading:11001391-Lung Neoplasms,
pubmed-meshheading:11001391-Male,
pubmed-meshheading:11001391-Middle Aged,
pubmed-meshheading:11001391-Organoplatinum Compounds,
pubmed-meshheading:11001391-Quality of Life,
pubmed-meshheading:11001391-Questionnaires,
pubmed-meshheading:11001391-Retrospective Studies
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients.
|
| pubmed:affiliation |
Oncologia Medica Complementare, Istituto Regina Elena, Rome, Italy. garufi@sirio-oncology.it
|
| pubmed:publicationType |
Journal Article
|